Skip to content
Screener

NeoGenomics NEO Client direct billing — NET REVENUE

Other product segments

Commercial insurance
$36.27M+26.1%
Medicare and other government
$27.43M
Self-pay
$0-100%

Similar metrics at other companies

Advanced Micro Devices logo
AMDClient — Net revenue
$3.06B+22.5%
Visa logo
VClient incentives — Net revenue
-$4.68B-17.8%
Raymond James Financial logo
RJFClient account and other fees — Revenue
$65M+3.2%
HireQuest logo
HQIHirequest Direct — Revenue (Gross)
$3.44M-4.2%
Blackrock logo
BLKRevenue By Client Type — Revenue
$5.73B+28.6%
Advanced Micro Devices logo
AMDClient and Gaming — Net revenue
$3.84B+6.1%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Client direct billing$137,956$131,157$269,545$253,195
Commercial insurance36,27328,76667,21153,623
Medicare and other government27,42721,38751,57242,488
Self-pay2059
Total net revenue$201,656$181,330$388,328$349,365

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's client direct billing — NET REVENUE?
NeoGenomics (NEO) reported client direct billing — NET REVENUE of $137.96M in Q2 2026.
How has NeoGenomics's client direct billing — NET REVENUE changed year-over-year?
NeoGenomics's client direct billing — NET REVENUE increased by 5.2% year-over-year, from $131.16M to $137.96M.
What is the long-term trend for NeoGenomics's client direct billing — NET REVENUE?
Over 4 years (2021 to 2025), NeoGenomics's client direct billing — NET REVENUE has grown at a 19.7% compound annual growth rate (CAGR), from $252.62M to $518.84M.
What does client direct billing — NET REVENUE mean?
This metric represents the total net revenue generated from diagnostic testing services billed directly to healthcare providers, hospitals, and clinical institutions. It reflects the company's ability to capture market share within the clinical diagnostics space by establishing direct commercial relationships with ordering physicians and facilities. Growth in this segment indicates successful penetration of the clinical services market and effective management of direct-to-provider billing channels.

Ask your AI about NeoGenomics's client direct billing — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude